BEI Medical Systems Reports Results of Clinical Trials At FIGO World Congress; Gynecologists Speak About Hydro ThermAblator Treatment.

Business Editors & Medical Writers

TETERBORO, N.J.--(BUSINESS WIRE)--Sept. 14, 2000

BEI Medical Systems Company, Inc. (NASDAQ: BMED), reports positive reaction to gynecologists' presentations about its Hydro ThermAblator(R) ("HTA(R)") at the 16th FIGO World Congress of Gynecology and Obstetrics which was held recently at the Washington Convention Center, Washington, DC.

The HTA is an investigational device for the treatment of excessive uterine bleeding and is currently in Phase III clinical trial under an investigational device exemption ("IDE") approved by the Food and Drug Administration ("FDA").

Richard W. Turner, president and chief executive officer of BEI Medical Systems, stated that, "We are pleased with the interest the HTA received at the show following the presentations by three gynecologists who addressed the Congress and presented papers about the HTA. Gynecologists attending the show expressed particular interest in the HTA's ability to provide direct visualization of the uterine cavity through a hysteroscope and its ability to treat abnormally sized and shaped uterine cavities."

Dr. Franklin Loffer, a leading U.S. gynecologist and a participant in the HTA clinical trial, reported on the preliminary results of patients in the trial 12 months following treatment. This 12 month post-treatment follow-up data is to be included in the company's PMA (pre-market approval) submission to the FDA. Another noted U.S. gynecologist, Dr. Jay M. Berman, who also participated in the Phase III clinical trial, presented a paper in which he compared clinical and economic outcomes for hospital-based abdominal hysterectomy and traditional rollerball ablation to endometrial ablation using the HTA in an outpatient surgery center and in the office setting. Dr. Berman is on the faculty of Wayne State University School of Medicine, in Detroit, Michigan, and also has a private practice in obstetrics and gynecology in Southfield, Michigan.

Finally, Dr. Mohamed Hefni a gynecologist in the United Kingdom who has been using the HTA, presented a paper based on 51 patients he had treated in the United Kingdom with the HTA and the follow-up of 31 of the patients for 9 to 18 months. Dr. Hefni reported 55 percent of these patients had no menstrual bleeding, and an additional 32 percent had only light menstrual bleeding following treatment with the HTA for their excessive menstrual bleeding.

Mr. Turner stated, "Filing of the 12 month post-treatment follow-up data as the final portion of the company's Phase III PMA with the FDA is imminent, pending final review by the company's outside counsel and the Clinical Research Organization."

BEI Medical Systems Company, Inc., based in Teterboro, NJ, is a development-stage company focused on gynecology. The company is conducting a clinical trial of its sole product, the Hydro ThermAblator, or HTA system, a proprietary system that is intended to treat menorraghia, or excessive uterine bleeding. BEI Medical Systems(R), Hydro ThermAblator(R) and HTA(R) are registered trademarks of BEI Medical Systems Company, Inc., in the United States and certain foreign countries.

Except for historical information, this news release may be deemed to contain forward-looking statements that involve risks and uncertainties, including statements with respect to: timely development; acceptance and pricing of the HTA system; whether the HTA proves to be safe and effective in U.S. and international clinical trials under applicable regulatory guidelines; receipt of required FDA approval; the impact of competitive products and pricing; and general economic conditions as they affect BEI Medical's customers, as well as other risks detailed from time to time in the company's reports to the Securities and Exchange Commission, including the company's Form 10-K Annual Report.